Alterations in Ki67 Labeling Following Treatment of Poorly Differentiated Neuroendocrine Carcinomas
Vyas M, Tang L, Rekhtman N, Klimstra D. Alterations in Ki67 Labeling Following Treatment of Poorly Differentiated Neuroendocrine Carcinomas. The American Journal Of Surgical Pathology 2020, 45: 25-34. PMID: 33177340, PMCID: PMC8549487, DOI: 10.1097/pas.0000000000001602.Peer-Reviewed Original ResearchConceptsHigh-grade neuroendocrine neoplasmsWD-NETsKi67 indexPD-NECsPoor-differentiated neuroendocrine carcinomasWell-differentiated neuroendocrine tumorsTreatment-associated alterationsSemi-quantitative scoreLow Ki67WHO G1Neuroendocrine carcinomaAdenoneuroendocrine carcinomaNeuroendocrine tumorsNeuroendocrine neoplasmsPrognostic significanceG2 gradeKi67 labelingDiagnostic pitfallsWHO gradePosttreatment groupStudy cohortAnatomical sitesKi67Pretreatment groupPosttreatment samples
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply